Advance Search
YAN Tingjun. Application of combined dynamic detection of serum tumor markers in the diagnosis and treatment of breast cancer[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 42-45, 48. DOI: 10.7619/jcmp.201911012
Citation: YAN Tingjun. Application of combined dynamic detection of serum tumor markers in the diagnosis and treatment of breast cancer[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 42-45, 48. DOI: 10.7619/jcmp.201911012
shu

Application of combined dynamic detection of serum tumor markers in the diagnosis and treatment of breast cancer

  • Department of Blood Transfusion, Ji′nan Third People′s Hospital, Ji′nan, Shandong, 250132

More Information
  • Received Date: April 12, 2019
  • Accepted Date: May 09, 2019
  • Available Online: February 22, 2021
  • Published Date: June 14, 2019
    Graphical Abstract
    • Abstract
  •   Objective  To explore the clinical value of differently and dynamically combined detection of serum carbohydrate antigen 153(CA153), serum carbohydrate antigen 125 (CA125) and osteopontin (OPN) for the diagnosis and monitoring of breast cancer.
      Methods  A total of 98 patients with breast cancer, 50 patients with benign breast lesions and 50 healthy donors were as breast cancer group, benign control group and normal control group. The levels of serum CA153, CA125 in three groups were detected through electrochemiluminescence, and the level of OPN was measured by enzyme-linked immunosorbent. The correlations between the levels of CA153, CA125, OPN and benign, malignant breast diseases were analyzed.
      Results  ① The levels of serum CA153, CA125 and OPN in the breast cancer group were obviously higher than the benign group and healthy control group (P < 0.01). There was no significant difference between the benign control group and the normal control group (P>0.05). ② The serum CA153, CA125 and OPN levels in patients with breast cancer were not correlated with age and tumor location (P>0.05), while were significantly correlated with the tumor size, clinical staging, metastasis, recurrence and post-treatment. The levels of serum CA153, CA125 and OPN in the breast cancer patients with high stagings (Ⅲ, Ⅳ) were significantly higher than those with low stagings (Ⅰ, Ⅱ) (P < 0.01), and there were significant differences between patients with lymph node metastasis and those with non-metastasis, between recurrence patients and those without (P < 0.01). Furthermore, the levels of serum CA153, CA125 and OPN after treatment were obviously decreased compared with treatment before (P < 0.01). ③ The sensitivity and accuracy of combined detection of serum CA153, CA125 and OPN were significantly improved compared with detection alone or partial combined detection.
      Conclusion  The diagnostic detection of serum CA153, CA125 and OPN in combination for breast cancer has significantly higher detection rate, and decreased misdiagnosis and missed diagnosis, which is helpful for early clinical discovery and intervention. Meanwhile, the dynamically combined detection can monitor the tumor metastasis and recurrence, assess the prognosis.
    • FullText(HTML)
    • References (15)
  • [1]
    任东. 彩超联合血清可溶性E-钙黏蛋白及癌胚抗原检测用于乳腺癌诊断的灵敏度与特异度探究[J]. 中国妇幼保健, 2019, 34(6): 1404-1408. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201906065.htm
    [2]
    傅丽敏, 程雪, 张小薇. 血清肿瘤标记物癌胚抗原、CA153和CA125检测对乳腺癌的临床诊断价值[J]. 检验医学, 2016, 54(20): 104-107. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS201620032.htm
    [3]
    周晓燕, 胡玉莲, 王刚平, 等. 免疫组化表达在乳腺癌前驱病变与微侵润性癌鉴别诊断中的应用[J]. 中国临床实用医学, 2014, 15(3)19-21. doi: 10.3760/cma.j.issn.1673-8799.2014.03.008
    [4]
    徐龙, 张冠中, 郑振东, 等. 血清CEA及CA153连续且显著降低对晚期乳腺癌无影像学进展的判定价值[J]. 中国肿瘤临床, 2016(19): 67-68. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201619011.htm
    [5]
    李学瑞, 廖宁, 张国淳, 等. 分子标记物预测乳腺癌腋窝前哨淋巴结转移研究[J]. 实用医学杂志, 2012, 28(23): 3888-3891. doi: 10.3969/j.issn.1006-5725.2012.23.013
    [6]
    Bahrami A, Mortazavizadeh M R, Yazdi M F, et al. Serial tumor markers serum carcinoembryonic antigenand cancer antigen 153 assays in detecting symptomaticmetastasis in breast cancer patients[J]. East MediterrHealth J, 2012, 18(10): 1055-1059.
    [7]
    贾华, 于祥林. 血清CA153、CEA和CA125水平与乳腺癌病情转归的关系分析[J]. 中国实验诊断学, 2013, 17(12): 2218-2220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD201312034.htm
    [8]
    南永刚, 许建林, 李楠, 等. CA153、CA125联合her-2检测在乳腺癌各临床分期诊断中的应用[J]. 现代肿瘤医学, 2015, 24(19): 3070-3073. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201619019.htm
    [9]
    Chen M Y, Gao W W, Xu Y H, et al. The significance of her 2 gene detection in breast cancer diagnosis and treatment[J]. Modern Oncology, 2015, 23(18): 2701-2705. http://en.cnki.com.cn/Article_en/ http://search.cnki.net/down/default.aspx?filename=SXZL201518047&dbcode=CJFD&year=2015&dflag=pdfdown
    [10]
    Alsalloom A A. An update of biochemical markers of hepatocellular Caicinoma[J]. Int J Health Sci(Qassim), 2016, 10(1): 121-136. http://pubmedcentralcanada.ca/pmcc/articles/PMC4791163/
    [11]
    钟琼. 血清CA153、CA125、CEA和PRL检测对乳腺癌术后治疗的指导意义[J]. 赣南医学院学报, 2015, 35(6): 913-917. doi: 10.3969/j.issn.1001-5779.2015.06.025
    [12]
    王明明. 分子标记物CEA、TSGF、OPN和CA125在乳腺癌及增生性病变诊断中的应用[J]. 临床医药文献杂志, 2015, 2(13): 2501-2503. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWX201513027.htm
    [13]
    葛玉兵, 刘海燕, 史硕达. 钼靶X射线摄片与血清CA15-3、CEA和OPN联检对乳腺癌的临床诊断价值[J]. 放射免疫学杂志, 2013, 26(1): 28-30. https://www.cnki.com.cn/Article/CJFDTOTAL-FSMY201301013.htm
    [14]
    王文尚, 陆莹莹, 梁志聪, 等. 乳腺癌行乳腺钼靶X射线摄片联合血清CA15-3、CEA及OPN的诊断价值[J]. 现代医用影像学, 2015, 24(3): 299-302. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYY201503004.htm
    [15]
    Printzcancer C. Breast cancer mortality rates decline internationally, with some major exceptions[J]. Cancer, 2017, 123(7): 1085-1089. doi: 10.1002/cncr.30670/abstract
    • Related Articles

  • Related Articles

    [1]WANG Jie, GU Ting, SONG Jixin, WU Yinqiu, DAI Chun, DAI Hua. Effects of human adaptor protein LNK on proliferation and invasion ability of non-small cell lung cancer cells[J]. Journal of Clinical Medicine in Practice, 2023, 27(10): 31-35. DOI: 10.7619/jcmp.20230166
    [2]TIAN Ling. Effect of Urinary Kallidinogenase for Injection on nervous function in patients with acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 101-103. DOI: 10.7619/jcmp.202008027
    [3]REN Kaiming. Influence of long non-coding RNA KCNQ1 overlapping transcript 1 on cellular proliferation, migration and invasive ability of lung squamous cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2019, 23(9): 1-4, 8. DOI: 10.7619/jcmp.201909001
    [7]ZHU Jinli. Effect of urinary kallidinogenase combined with troxerutin and cerebroprotein hydrolysate injection on coagulation and neurological function of patients with acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2016, (9): 17-20. DOI: 10.7619/jcmp.201609005
    [9]MENG Yun, XHOU Hongbin, XHU Yanliang. Influence of arterial thrombolysis combined with urinary kallidinogenase on the prognosis of patients with acute posterior circulation cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2014, (9): 51-54. DOI: 10.7619/jcmp.201409014
    [10]LIU Zhenqi, ZHENG Ying. Impact of urinary kallidinogenase to NIHSS scores in patients with cerebral watershed infarcts[J]. Journal of Clinical Medicine in Practice, 2012, (21): 90-91,96.

  • Cited by

    Periodical cited type(1)

    1. 吴艳，相开放. 甲状腺乳头状癌组织中MTAP、SETD2表达水平及其与临床病理特征的关系. 黑龙江医药. 2023(03): 704-706 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (259) PDF downloads (6) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return